Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
CASH FLOWS FROM OPERATING ACTIVITIES:
NET (LOSS) INCOME	$ (3,581,213)	$ (6,250,952)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	138,425	141,147
Issuance of common stock, warrants and options for services	38,670	36,982
Modification of stock options and warrants	36,990	30,186
Employee option cost	837,458	362,077
Common stock contributed to 401(k) plan	38,486	33,258
Impairment loss on abandonment of patents	7,955	0
Loss on retired equipment	1,049	237
Deferred rent	(1,509)	(730)
Gain/loss on derivative instruments	(956,470)	1,946,395
Change in assets and liabilities:
Decrease (increase) in receivables	448,703	(457,521)
Decrease in deferred rent	153,105	166,744
Decrease (increase) in prepaid expenses	235,343	(1,913,949)
Decrease in inventory used for R&D and manufacturing	200,858	89,903
Decrease in accounts payable	(127,006)	(629,729)
(Decrease)/increase in accrued expenses	(84,590)	12,050
Decrease in due to employees	(2,847)	(634)
Increase in deposits held	5,000	0
NET CASH USED IN OPERATING ACTIVITIES	(2,611,593)	(6,434,536)
CASH FLOWS FROM INVESTING ACTIVITIES:
Increase in restricted cash	0	(15)
Purchases of equipment	(16,467)	(27,733)
Expenditures for Patent costs	(306)	(1,982)
NET CASH USED IN INVESTING ACTIVITIES	(16,773)	(29,730)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	3,810,000	0
Proceeds from exercise of stock options and warrants	0	749,794
Payments on convertible debt	(1,980,000)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,830,000	749,794
NET DECREASE IN CASH AND CASH EQUIVALENTS	(798,366)	(5,714,472)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	4,260,594	26,568,243
CASH AND CASH EQUIVALENTS, END OF PERIOD	3,462,228	20,853,771
Issuance of warrants:
Increase in derivative liabilities	(2,146,667)	0
Decrease in additional paid-in capital	2,146,667	0
Total	0	0
Issuance of additional shares:
Increase in common stock	(8,333)	0
Increase in additional paid-in capital	(241,667)	0
Decrease in additional paid-in capital	250,000	0
Total	0	0
Exercise of derivative liabilities:
Decrease in derivative liabilities	0	61,615
Increase in additional paid-in capital	0	(61,615)
Total	0	0
Modification of warrants:
Increase in additional paid-in capital	(325,620)	0
Decrease in additional paid-in capital	325,620	0
Total	0	0
Patent costs included in accounts payable:
Increase in patent costs	15,277	65,606
Increase in accounts payable	(15,277)	(65,606)
Total	0	0
Equipment costs included in accounts payable:
Increase in research and office equipment	4,703	4,422
Increase in accounts payable for Equipment costs	(4,703)	(4,422)
Total	0	0
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash expenditures for interest expense	$ 218,502	$ 41,402